Seppo Mäkinen, previously a ValiRx Non-Executive Director, has more than 30 years of senior advisory and executive experience in board level strategic leadership and venture capital management on life science. His career includes ten years as director in Life Sciences at Sitra (Finnish Government Fund), followed by 13 years as co-founder and Managing Partner in Bio Fund Management Oy. In 2010, Seppo founded Taikon Advisor Oy, a Finnish management consultancy firm focusing on advising and investing in life sciences ventures. He stepped down from the ValiRx Board in May 2017.
Andrew King has almost twenty years’ experience working in the biotech and life-science sectors. He served for nearly ten years as Finance Director of the extremely successful AIM listed biotech company, NeuTec Pharma Limited, leading the business through its IPO to its subsequent sale in 2006 to Novartis Pharma AG for £305 million. He has experience across a range of sectors and has served as Finance Director and company secretary to a number of organisations including Hutchison Whampoa (Europe) Limited, Utility Cable plc and Umbro.com Limited. Most recently he served for five years as CFO to Smart Matrix Limited, a start-up medtech business spun out of a medical research charity. Since 2016 he has acted as an Associate Partner with St. James’s Place Wealth Management plc. He is a qualified Chartered Accountant (Price Waterhouse) and has a degree in law.